Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dupixent Dip Dogs Sanofi Efforts To Deal With Diabetes Decline

Executive Summary

Although sales of the closely-watched atopic dermatitis drug Dupixent disappointed in the first quarter, the French major sees the fall as an inventory-related blip and has high hopes that the therapy, as well as the contribution of recently acquired Bioverativ, will help fill the revenue hole left by Lantus.

You may also be interested in...

Strong Sobi With New Asset: A Takeover Target For Sanofi?

Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?

Sanofi In Pole Position In Oral Type 1 Diabetes With Zynquista Filings

The French drugmaker and partner Lexicon now have a PDUFA date of March 22 next year for their dual inhibitor of SGLT-1 and SGLT-2 which is well placed to become the first oral antidiabetic to get the green light for use by adults with the type 1 form of the disease, in combination with insulin.

Sanofi's Generics Business To Be Sold To Private Equity Firm, Advent

Sanofi will have €1.9bn to add to its war-chest when it concludes the sale of its European generics business.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts